eNeura, a Baltimore-based company that makes a device to treat migraines, closed a Series D investment round.
When: Tuesday, February 13, 2018 from 5:00 PM to 7:00 PM EST
Where: Bar Louie 150 Gibbs St Rockville, MD 20850
Join BioBuzz and sponsor BioIT Solutions in Rockville at Bar Louie on February 13th, 2018 from 5 – 7pm. Only a 5 minute walk from the Rockville Metro, please join us for this exciting event. BioIT Solutions offers a range of services from enterprise systems built on their 1Platform4® Suite for advanced computational, workflow, and data management systems to IT strategy, architecture and management consulting. The 1Platform4® Suite consists of a software foundation on which various highly configurable modules are assembled and tailored to each client’s specifications and needs.
Orgenesis Inc., (OTCQB:ORGS), a service and research company in the field of the regenerative medicine industry with a focus on cell therapy development and manufacturing for advanced medicinal products, today announced it has entered into an agreement with Adva Biotechnology Ltd., an innovator of enhanced bioprocessing solutions, for the development of an automated culturing system for use in the provision of contract manufacturing services, as well as Orgenesis’s therapeutic development. This system has the potential to enable cost-efficient and automated manufacturing for autologous cell therapies.
On Sunday, Feb. 25, 2018, the Organization for Rare Diseases India (ORDI), is holding simultaneous walks or races in Bengaluru, Mumbai, and Washington, D.C.
Dovetailing off our Top 27 Venture Players report, we’ve put together the 19 largest AEC and real estate venture rounds of the past year. There were plenty of surprises.
Imagine instead of a pill, a doctor prescribes a game for a child with attention deficit disorder. Or imagine patients dealing with substance abuse being prescribed assessments they can do via a mobile device to track progress.
The University System of Maryland (USM) has selected NextStep Robotics, a start-up company that has developed a personalized robotic therapy to help relieve discomforts of “foot drop” syndrome in recovering stroke patients. The robotic therapy is based on research in the University of Maryland, Baltimore (UMB) School of Medicine, Baltimore Veterans (VA) Affairs Medical Center, and University of Maryland, College Park (UMCP) A. James Clark College of Engineering, as recipient of the second investment from the recently established Maryland Momentum Fund.
Mid-Atlantic Angels, LLC (MAA) approaches its 2018 programming in an environment of economic optimism that leverages the economic upsurge of 2017. With the strengthening economy and accompanying confidence, angel investment is expected to surge and contribute to the growth of a vibrant regional economic landscape. The aim is to help create successful businesses while generating a return on investment for MAA member investors. In addition to scheduling a full slate of five Capital Cycles for 2018 in which entrepreneurial companies pitch for capital, MAA is adding more investor members, has lined up a valuable series of investor/entrepreneur workshops, has established a cadre of loyal sponsor organizations, is increasing its outreach to investment and entrepreneurial oriented organizations in the Frederick region, and is expanding its Board to better meet the needs of MAA and its communities.
Top life science companies perform cutting-edge research and make transformational discoveries throughout the County from the I-270 corridor of Gaithersburg and Germantown to White Oak. Add in the federal presence of the NIH and FDA, along with top talent, and tap into our strong momentum for BioHealth success. The business models vary yet our companies have important assets in common: a commitment to diversity of people, places and ideas and a spirit of innovation. Meet some of our impressive CEOs and company heads that showcase life science excellence in the County in our Think Success video series.
Join WIB–Capital Region on February 21, 2018 for a panel discussion with industry experts that will help demystify venture capital funding in the biotech space.